Lupin launches Arformoterol Tartrate Inhalation Solution in US
Mumbai: Global pharma major, Lupin Limited, has recently announced the launch of the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL, is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is for use by nebulization only.
Read also: Lupin application for Pegfilgrastim biosimilar accepted by USFDA
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
